{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:13Z","timestamp":1787988013859,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Androgen receptor signaling inhibitors (ARSi) have significantly improved clinical outcomes in men with prostate cancer (PCa). Preliminary data suggest the potential for ARSi to enhance PSMA expression in patients with mCRPC. In this analysis, we present preliminary dosimetry results from mCRPC patients treated with either [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T radioligand therapy (RLT) in combination with ARSi compared to a Control Group of patients receiving [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis was performed at a single center, including 50 patients diagnosed with mCRPC who underwent their first cycle of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (n\u2009=\u200937) or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T (n\u2009=\u200913) RLT\u2009\u00b1\u2009concomitant ARSi treatment (abiraterone or enzalutamide). Patients were divided into a Combination Group (RLT\u2009+\u2009ARSi,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925) and a Control Group (RLT only,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925). Quantitative SPECT imaging was performed at 3 time points: 24\u00a0h (+\u2009CT), 48\u00a0h, and 72\u00a0h post-administration of the initial cycle of RLT. Tumor lesions were segmented using the 24\u00a0h SPECT images, while organs-at-risk (kidney, spleen, liver) were delineated on the corresponding CT. Absorbed doses were calculated by applying a mono-exponential curve fit, incorporating local density scaling. Dosimetry results were evaluated separately for each radioligand.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 148 tumor lesions were included in this analysis (median 3 lesions per patient). The median tumor absorbed dose was comparable between the Combination Group and the Control Group: [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (2.1\u2009\u00b1\u20094.0\u00a0Gy\/GBq vs 1.5\u2009\u00b1\u20091.7\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.24) and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T (1.2\u2009\u00b1\u20091.2\u00a0Gy\/GBq vs 1.2\u2009\u00b1\u20093.5\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.21). Furthermore, the median absorbed dose in organs-at-risk was comparable between the two groups in [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617: Kidneys: 0.28\u2009\u00b1\u20090.11\u00a0Gy\/GBq vs 0.27\u2009\u00b1\u20090.13\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.90; Spleen: 0.05\u2009\u00b1\u20090.05\u00a0Gy\/GBq vs 0.06\u2009\u00b1\u20090.05\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.75; Liver: 0.08\u2009\u00b1\u20090.03\u00a0Gy\/GBq vs 0.07\u2009\u00b1\u20090.04\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.75). A statistically significant difference was noted in kidneys and liver for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T: Kidneys: 0.21\u2009\u00b1\u20090.10\u00a0Gy\/GBq vs 0.30\u2009\u00b1\u20090.08\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.01; Spleen: 0.02\u2009\u00b1\u20090.02\u00a0Gy\/GBq vs 0.04\u2009\u00b1\u20090.03\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.20; Liver: 0.02\u2009\u00b1\u20090.01\u00a0Gy\/GBq vs 0.04\u2009\u00b1\u20090.01\u00a0Gy\/GBq,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.01.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07967-3","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:50:15Z","timestamp":1781164215000},"page":"6442-6451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&amp;T therapy: dosimetry results"],"prefix":"10.1007","volume":"53","author":[{"given":"Josef","family":"Zahner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Ells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Antic","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Tiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can D.","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"B\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"7967_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"key":"7967_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215417","author":"A Jacob","year":"2021","unstructured":"Jacob A, Raj R, Allison DB, Myint ZW. Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13215417.","journal-title":"Cancers (Basel)"},{"key":"7967_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01537-3","volume":"38","author":"M Parsi","year":"2021","unstructured":"Parsi M, Desai MH, Desai D, Singhal S, Khandwala PM, Potdar RR. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021;38:89. https:\/\/doi.org\/10.1007\/s12032-021-01537-3.","journal-title":"Med Oncol"},{"key":"7967_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","volume":"75","author":"LM Unterrainer","year":"2024","unstructured":"Unterrainer LM, Calais J, Bander NH. Prostate-specific membrane antigen: gateway to management of advanced prostate cancer. Annu Rev Med. 2024;75:49\u201366. https:\/\/doi.org\/10.1146\/annurev-med-081522-031439.","journal-title":"Annu Rev Med"},{"key":"7967_CR5","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0231.","journal-title":"Clin Cancer Res"},{"key":"7967_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjogreen-Gleisner K. MIRD pamphlet No. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57:151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012.","journal-title":"J Nucl Med"},{"key":"7967_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112691","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bader H, Bartholoma M, Maus S, Burgard C, Linxweiler J, et al. Addition of standard Enzalutamide medication shows synergistic effects on response to [(177)Lu]Lu-PSMA-617 radioligand therapy in mCRPC patients with imminent treatment failure-preliminary evidence of pilot experience. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14112691.","journal-title":"Cancers (Basel)"},{"key":"7967_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071696","author":"F Rosar","year":"2022","unstructured":"Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, et al. Upregulation of PSMA expression by Enzalutamide in patients with advanced mCRPC. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071696.","journal-title":"Cancers (Basel)"},{"key":"7967_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01048-4","volume":"13","author":"I Sonni","year":"2023","unstructured":"Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, et al. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13:95. https:\/\/doi.org\/10.1186\/s13550-023-01048-4.","journal-title":"EJNMMI Res"},{"key":"7967_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:291\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9.","journal-title":"Lancet Oncol"},{"key":"7967_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"7967_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050946","author":"LM Unterrainer","year":"2022","unstructured":"Unterrainer LM, Beyer L, Zacherl MJ, Gildehaus FJ, Todica A, Kunte SC, et al. Total tumor volume on (18)F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with (225)Ac-PSMA-I&T. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10050946.","journal-title":"Biomedicines"},{"key":"7967_CR13","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Sch\u00e4fers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786\u201392. https:\/\/doi.org\/10.2967\/jnumed.120.242057.","journal-title":"J Nucl Med"},{"key":"7967_CR14","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","volume":"8","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581\u201390. https:\/\/doi.org\/10.18632\/oncotarget.12240.","journal-title":"Oncotarget"},{"key":"7967_CR15","unstructured":"German Radiation Protection Ordinance (Strahlenschutzverordnung \u2013 StrlSchV). Ordinance on protection against the harmful effects of ionising radiation. Bonn, Germany: Federal Law Gazette (Bundesgesetzblatt), Part I; 2018. p. 2034\u20136"},{"key":"7967_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40658-023-00529-8","volume":"10","author":"S Resch","year":"2023","unstructured":"Resch S, Takayama Fouladgar S, Zacherl M, Sheikh GT, Liubchenko G, Rumiantcev M, et al. Investigation of image-based lesion and kidney dosimetry protocols for (177)Lu-PSMA-I&T therapy with and without a late SPECT\/CT acquisition. EJNMMI Phys. 2023;10:11. https:\/\/doi.org\/10.1186\/s40658-023-00529-8.","journal-title":"EJNMMI Phys"},{"key":"7967_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3174-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7967_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-022-06092-1","volume":"50","author":"A Delker","year":"2023","unstructured":"Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, et al. Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T\/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50:1280\u201390. https:\/\/doi.org\/10.1007\/s00259-022-06092-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7967_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030428","author":"F V\u00f6lter","year":"2021","unstructured":"V\u00f6lter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, et al. Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after (177)Lu-PSMA-617 radioligand therapy. Diagnostics Basel. 2021. https:\/\/doi.org\/10.3390\/diagnostics11030428.","journal-title":"Diagnostics Basel"},{"key":"7967_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J, D\u2019Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for (177)Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58:445\u201350. https:\/\/doi.org\/10.2967\/jnumed.116.178483.","journal-title":"J Nucl Med"},{"key":"7967_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7967_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147431","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, et al. Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147431.","journal-title":"Int J Mol Sci"},{"key":"7967_CR23","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1007\/s00259-025-07178-2","volume":"52","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, et al. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025;52:3700\u20138. https:\/\/doi.org\/10.1007\/s00259-025-07178-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7967_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00339-0","author":"L Emmett","year":"2025","unstructured":"Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, et al. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025. https:\/\/doi.org\/10.1016\/S1470-2045(25)00339-0.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07967-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:59Z","timestamp":1787986859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7967"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07967-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of Ludwig-Maximilians University (#24\u20130982).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients consented to imaging and subsequent therapy.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CDA has received honoraria from Astellas and Ipsen, and travel\/accommodation support from Astellas, Bristol Myers Squibb (BMS), Eisai, Janssen, and MSD. CL reports prior consulting activities for Blue Earth Diagnostics Ltd., PentixaPharm, Pfizer, and Novartis. JC reports grants from support to his institution from Novartis, Lantheus, Fusion Pharmaceuticals, Telix Pharmaceuticals and POINT biopharma. He also reports Consulting activities (advisory boards, speaker, blinded reader) for Advanced Accelerator Applications, Amgen, Arsenal Bio, Astellas, Bayer, Blue Earth Diagnostics Inc., Curium Pharma, Coretag, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Keosys, Lightpoint medical, Lantheus, Monrol, Mariana Oncology, Novartis, Nucleus Radiopharma, Pfizer, POINT biopharma, Progenics, Radiomedix, Radiopharm Theranostics, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceuticals, outside of the submitted work. RW has received speaker honoraria from Novartis\/AAA and PentixaPharm and has served on advisory boards for Novartis\/AAA and Bayer\n                      .\n                      LU reports fees from Novartis (speaker), Telix (consultant) and Astellas Pharma Inc. (speaker) outside of the submitted work.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}